Selective cannabinoid receptor type 2 (CB2) agonists: Optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain

Journal of Medicinal Chemistry

Volumn 56, Issue 14, 2013, Pages 5722-5733

  Hollinshead, Sean P ^a   Tidwell, Michael W ^a,b   Palmer, John ^a   Guidetti, Rossella ^a   Sanderson, Adam ^a   Johnson, Michael P ^a   Chambers, Mark G ^a   Oskins, Jennifer ^a   Stratford, Robert ^a,c   Astles, Peter C ^a  

^a ELI LILLY AND COMPANY   (United States)

^b SOUTHWEST RESEARCH INSTITUTE   (United States)

^c XAVIER UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 (2 CHLOROPHENYL) 2 METHYL 6 (4 METHYLPIPERAZIN 1 YL) 9 (2 METHYLSULFONYLETHYL)PURINE; 8 (2 CHLOROPHENYL) 2 METHYL 6 (4 METHYLPIPERAZIN 1 YL) 9 TETRAHYDROPYRAN 4 YL PURINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; DICLOFENAC; PURINE DERIVATIVE; THIENOPYRIMIDINE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; INFLAMMATORY PAIN; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; DOGS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HEK293 CELLS; HUMANS; MALE; OSTEOARTHRITIS; PURINES; RATS; RATS, INBRED LEW; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880873288     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400305d     Document Type: Article

References (53)

1. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
2. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65
3. Voth, E. A.; Schwartz, R. H. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana Ann. Intern. Med. 1997, 126, 791-798
4. Gaoni, Y.; Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish J. Am. Chem. Soc. 1964, 86, 1646-1647
5. Rice, A. S. Should cannabinoids be used as analgesics for neuropathic pain? Nature Clin. Pract. Neurol. 2008, 4, 654-655
6. Baker, D.; Pryce, G.; Giovannoni, G.; Thompson, A. J. The therapeutic potential of cannabis Lancet Neurol. 2003, 2, 291-298
7. Adams, I. B.; Martin, B. R. Cannabis: pharmacology and toxicology in animals and humans Addiction 1996, 91, 1586-1614
8. Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids Nature 1993, 365, 61-65
9. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990, 346, 561-564
10. Gerard, C. M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis Biochem. J. 1991, 279 (Part 1) 129-134
11. Reggio, P. H. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors Curr. Pharm. Des. 2003, 9, 1607-1633
12. Cabral, G. A.; Griffin-Thomas, L. Emerging Role of the CB2 Cannabinoid Receptor in Immune Regulation and Therapeutic Prospects Expert Rev. Mol. Med. 2009, 11, e3
13. Cabral, G. A.; Raborn, E. S.; Griffin, L.; Dennis, J.; Marciano-Cabral, F. CB2 receptors in the brain: role in central immune function Br. J. Pharmacol. 2008, 153, 240-251
14. Fernández-Ruiz, J.; Romero, J.; Velasco, G.; Tolón, R. M.; Ramos, J. A.; Guzmán, M. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol. Sci. 2007, 28, 39-45
15. Van Sickle, M. D.; Duncan, M.; Kingsley, P. J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J. S.; Marnett, L. J.; Di Marzo, V.; Pittman, Q. J.; Patel, K. D.; Sharkey, K. A. Identification and functional characterization of brainstem cannabinoid CB2 receptors Science 2005, 310, 329-332
16. Herkenham, M.; Lynn, A. B.; Little, M. D.; Johnson, M. R.; Melvin, L. S.; de Costa, B. R.; Rice, K. C. Cannabinoid receptor localization in brain Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 1932-1936
17. Guindon, J.; Hohmann, A. G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain Br. J. Pharmacol. 2008, 153, 319-334
18. Anand, U.; Otto, W. R.; Sanchez-Herrera, D.; Facer, P.; Yiangou, Y.; Korchev, Y.; Birch, R.; Benham, C.; Bountra, C.; Chessell, I. P.; Anand, P. Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons Pain 2008, 138, 667-680
19. Valenzano, K. J.; Tafesse, L.; Lee, G.; Harrison, J. E.; Boulet, J. M.; Gottshall, S. L.; Mark, L.; Pearson, M. S.; Miller, W.; Shan, S.; Rabadi, L.; Rotshteyn, Y.; Chaffer, S. M.; Turchin, P. I.; Elsemore, D. A.; Toth, M.; Koetzner, L.; Whiteside, G. T. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy Neuropharmacology 2005, 48, 658-672
20. Yao, B. B.; Hsieh, G. C.; Frost, J. M.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Zhu, C. Z.; Pai, M.; Chandran, P.; Salyers, A. K.; Wensink, E. J.; Honore, P.; Sullivan, J. P.; Dart, M. J.; Meyer, M. D. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models Br. J. Pharmacol. 2008, 153, 390-401
21. Giblin, G. M. P.; O'Shaughnessy, C. T.; Naylor, A.; Mitchell, W. L.; Eatherton, A. J.; Slingsby, B. P.; Rawlings, D. A.; Goldsmith, P.; Brown, A. J.; Haslam, C. P.; Clayton, N. M.; Wilson, A. W.; Chessel, I. P.; Wittington, A. R.; Green, R. Discovery of 2-[(2,4-Dichlorophenyl)amino]- N -[(tetrahydro-2 H -pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain J. Med. Chem. 2007, 50, 2597-2600
22. Steiner, H.; Bonner, T. I.; Zimmer, A. M.; Kitai, S. T.; Zimmer, A. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 5786-5790
23. Herzberg, U.; Eliav, E.; Bennett, G. J.; Kopin, I. J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain Neurosci. Lett. 1997, 221, 157-160
24. Thakur, G. A.; Tichkule, R.; Bajaj, S.; Makriyannis, A. Latest advances in cannabinoid receptor agonists Expert Opin. Ther. Pat. 2009, 19, 1647-1673
25. Ashton, J. C. Cannabinoids for the treatment of inflammation Curr. Opin. Invest. Drugs 2007, 8, 373-384
26. Croxford, J. L.; Miller, S. D. Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212 J. Clin. Invest. 2008, 111, 1231-1240
27. Cheng, Y.; Hitchcock, S. A. Targeting cannabinoid agonists for inflammatory and neuropathic pain Expert Opin. Ther. Pat. 2007, 16, 951-965
28. Riether, D. Selective cannabinoid receptor 2 modulators: a patent review 2009-present Expert Opin. Ther. Pat. 2012, 22, 495-510
29. Leleu-Chavain, N.; Body-Malapel, M.; Spencer, J.; Chavatte, P.; Desreumaux, P.; Millet, R. Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents Curr. Med. Chem. 2012, 19, 3457-3474
30. Trotter, B. W.; Nanda, K. K.; Burgey, C. S.; Potteiger, C. M.; Deng, J. Z.; Green, A. I.; Hartnett, J. C.; Kett, N. R.; Wu, Z.; Henze, D. A.; Della Penna, K.; Desai, R.; Leitl, M. D.; Lemaire, W.; White, R. B.; Yeh, S.; Urban, M. O.; Kane, S. A.; Hartman, G. D.; Bilodeau, M. T. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy Bioorg. Med. Chem. Lett. 2011, 21, 2354-2358
31. Manley, P. J.; Zartman, A.; Paone, D. V.; Burgey, C. S.; Henze, D. A.; Della Penna, K.; Desai, R.; Leitl, M. D.; Lemaire, W.; White, R. B.; Yeh, S.; Urban, M. O.; Kane, S. A.; Hartman, G. D.; Bilodeau, M. T.; Trotter, B. W. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia Bioorg. Med. Chem. Lett. 2011, 21, 2359-2364
32. Gifford, A. N.; Bruneus, M.; Gatley, S. J.; Lan, R.; Makriyannis, A.; Volkow, N. D. Large receptor reserve for cannabinoid actions in the central nervous system J. Pharmacol. Exp. Ther. 1999, 288, 478-483
33. Berman, J. S.; Symonds, C.; Birth, R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial Pain 2004, 112, 299-306
34. Wissel, J.; Haydn, T.; Muller, J.; Brenneis, C.; Berger, T.; Poewe, W.; Schelosky, L. D. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial J. Neurol. 2006, 253, 1337-1341
35. Burns, T. L.; Ineck, J. R. Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain Ann. Pharmacother. 2006, 40, 251-260
36. Malan, T. P.; Ibrahim, M. M.; Deng, H.; Liu, Q.; Mata, H. P.; Vanderah, T.; Porreca, F.; Makriyannis, A. CB2 cannabinoid receptor-mediated peripheral antinociception Pain 2001, 93, 239-245
37. Ibrahim, M. M.; Deng, H.; Zvonok, A.; Cockayne, D. A.; Kwan, J.; Mata, H. P.; Vanderah, T. W.; Lai, J.; Porreca, F.; Makriyannis, A.; Malan, T. P., Jr. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 10529-10533
38. Ostenfeld, T.; Price, J.; Albanese, M.; Bullman, J.; Guillard, F.; Meyer, I.; Leeson, R.; Costantin, C.; Ziviani, L.; Nocini, P. F.; Milleri, S. Randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, Ibuprofen or placebo in patients with acute pain following third molar tooth extraction Clin. J. Pain 2011, 27, 668-676
39. Hollinshead, S. P.; Astles, P. C.; Chambers, M. G.; Johnson, M. P.; Palmer, J.; Tidwell, M. Discovery and optimization of novel purines as potent and selective CB2 agonists Bioorg. Med. Chem. Lett. 2012, 22, 4962-4966
40. 2-promoted cyclization reaction of 4,5-diaminopyrimidines with aldehydes leading to 6,8,9-trisubstituted purines Tetrahedron Lett. 2000, 41, 6559-6562
41. Gleeson, M. P. Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 2008, 51, 817-834
42. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
43. 35S]guanosine- 5′- O -(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay J. Pharmacol. Exp. Ther. 1999, 289, 946-955 Note: testing in CHO or SF9 membranes expressing the hCB2 receptor was found to be similar (data not shown).
44. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A. L.; Mitchell, R. L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors Mol. Pharmacol. 1995, 48, 443-450
45. Snyders, D. J.; Chaudhary, A. Compounds which display a high affinity for hERG ion channels are generally considered to have a higher risk of cardiotoxicity Mol. Pharmacol. 1996, 49, 949-955
46. Guingamp, C.; Gegout-Pottie, P.; Philippe, L.; Terlain, B.; Netter, P.; Gillet, P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry Arthritis Rheum. 1997, 40, 1670-1679
47. Kalbhen, D. A. Chemical model of osteoarthritis-a pharmacological evaluation J. Rheumatol. 1987, 14, 130-131
48. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J.-M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Brelière, J.-C.; Le Fur, G. L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor J. Pharmacol. Exp. Ther. 1998, 284, 644-650
49. Obach, R. S.; Lombardo, F.; Waters, N. J. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds Drug Metab. Dispos. 2008, 36, 1385-1405
50. Griffin, G.; Wray, E. J.; Tao, Q.; McAlliser, S. D.; Rorrer, W. K.; Aung, M.; Martin, B. R.; Abood, M. E. Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR 144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system Eur. J. Pharmacol. 1999, 377, 117-125
51. Leeson, P. D.; Springthorp, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-890
52. Jones, B. J.; Roberts, D. J. The quantitative measurement of motor incoordination in naive mice using an accelerating rotarod J Pharm. Pharmacol. 1968, 20, 302-304
53. McGregor, I. S.; Issakidis, C. N.; Prior, G. Aversive effects of the synthetic cannabinoid CP55,940 in rats Pharmacol., Biochem. Behav. 1996, 53, 657-664